REVOLUTION MEDICINES, INC.
REVOLUTION MEDICINES, INC.
REDWOOD CITY, CA
Loading...
Price History
Market Data
| Market Cap | 40.50B |
| P/E Ratio | - |
| P/B Ratio | 24.83 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | 0.44 |
| Current Ratio | 7.14 |
| Currency | USD |
Key Financial Metrics
-
Revenue
-1.13B
Net Income
-
EPS (Diluted)
-1.54B
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-1.18B
Returns & Efficiency
Return on Assets (ROA)
-48.0%
Return on Equity (ROE)
-69.3%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
2.35B
Total Debt
-
Debt to Equity
0.44x
Current Ratio
7.14
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| HQ | REDWOOD CITY, CA |
| Fiscal Year | 2025 |
Peers
AMGEN INC
AMGN
185.64B
P/E: --
GILEAD SCIENCES INC
GILD
168.66B
P/E: --
168.66B
P/E: --
BIOGEN IDEC INC.
BIIB
25.17B
P/E: --
BIOGEN INC.
BIIB
25.17B
P/E: --
MODERNA, INC.
MRNA
19.03B
P/E: --
Moderna, Inc.
MRNA
19.03B
P/E: --
13.58B
P/E: 32.5
Quick Links
Financial Statistics
Valuation
Market Cap$40.50B
P/E Ratio (TTM)-
Price to Book24.83
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-
Net Margin-
ROE-69.3%
ROA-48.0%
Leverage & Liquidity
Debt to Equity0.44
Current Ratio7.14
Total Debt-
Total Assets$2.35B
Stockholders' Equity$1.63B
Income Statement (FY 2025)
Revenue-
Gross Profit-
Operating Income$-1.18B
Net Income$-1.13B
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-1.54B
Cash & Equivalents$383.75M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 700 SAGINAW DR REDWOOD CITY, CA 94063 |
| Phone | 415-766-3638 |
| Incorporated | DE, US |
| EIN | 472029180 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 198.17M |
| Stockholders' Equity | $1.63B |
| Cash & Equivalents | $383.75M |
Recent Filings
View All
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2026-05-06
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-05-06
Local
4
Insider Transaction Report
Statement of changes in beneficial ownership
Filed: 2026-04-29
Local
DEFA14A
Additional Proxy Materials
Additional definitive proxy soliciting materials
Filed: 2026-04-28
Local
ARS
Annual Report to Shareholders
Annual report furnished to shareholders
Filed: 2026-04-28
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-04-27
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2026-04-27
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-04-16
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-15
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-15
Local
144
Proposed Sale Notice
Notice of proposed sale of securities
Filed: 2026-04-15
Local
305B2
Trust Indenture Application
Application for trust indenture qualification
Filed: 2026-04-15
Local
FWP
Free Writing Prospectus
Written communication re: securities offering
Filed: 2026-04-15
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-13
Local
424B5
Prospectus Supplement
Prospectus supplement filed under Rule 424(b)(5)
Filed: 2026-04-13
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | REVOLUTION MEDICINES, INC. |
| Ticker | RVMD |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | -- |
| Headquarters | REDWOOD CITY, CA |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 40.50B |
| Revenue | - |
| Net Income | -1.13B |
| P/E Ratio | - |
| EPS | - |
| Net Margin | - |
| ROE | -69.3% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...